title: Fluoxetine therapy in depersonalisation disorder: randomised controlled trial.
abstract: BACKGROUND
  Despite anecdotal reports that serotonin reuptake inhibitors may improve depersonalisation, there is no proven efficacious treatment for depersonalisation disorder.
  
  
  OBJECTIVE
  To investigate the efficacy of fluoxetine in the treatment of depersonalisation disorder.
  
  
  METHODS
  Fifty-four people who met DSM-IV criteria for depersonalisation disorder were recruited through newspaper advertisements, and 50 were randomised to a 10-week, double-blind trial of fluoxetine 10-60 mg/day or placebo. Primary outcome measures were the Dissociative Experiences Scale-Depersonalisation Factor, the Depersonalization Severity Scale and the Clinical Global Impression-Improvement (CGI-I) scale.
  
  
  RESULTS
  Intention-to-treat analysis revealed that fluoxetine (mean dosage 48 mg/day) was not superior to placebo except for a clinically minimal but statistically significantly greater improvement in CGI-I score in the fluoxetine group prior to covarying for anxiety and depression (2.9 v. 3.6). Depersonalisation was significantly more likely to improve if comorbid anxiety disorder improved.
  
  
  CONCLUSIONS
  Fluoxetine was not efficacious in treating depersonalisation disorder, despite the commonly reported clinical use of serotonin reuptake inhibitors for this condition.
authors.affiliation: Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA. daphne.simeon@mssm.edu
authors.forename: Daphne
authors.initials: D
authors.lastname: Simeon
authors.forename: Orna
authors.initials: O
authors.lastname: Guralnik
authors.forename: James
authors.initials: J
authors.lastname: Schmeidler
authors.forename: Margaret
authors.initials: M
authors.lastname: Knutelska
mesh_terms: D000328:Adult; D003861:Depersonalization / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors